

AMNEAL AND METSERA FORM STRATEGIC COLLABORATION TO CHANGE THE GLP-1 LANDSCAPE



Deep expertise in complex pharmaceutical manufacturing

Strong track record of delivering quality and innovation at scale

Trusted developer, manufacturer and distributor of diverse portfolio of 280+ pharmaceutical products

Extensive in-house capabilities, including API and sterile fill-finish manufacturing

Bringing High-Quality and Affordable Next-Generation Weight Loss Medicines to Market At Scale Globally



Rapidly advancing next-generation weight loss candidate medicines

Proprietary library of 20,000+ peptides and peptide/antibody conjugates

Addressing increasing demand and future needs of global obesity landscape with a broad R&D portfolio

Proven team singularly focused on bringing diverse portfolio of products to market

- 

Metsera recently announced highly competitive results from the Phase 1 clinical trial of its glucagon-like peptide-1 (GLP-1) receptor agonist injectable, MET-097
- 

Amneal will serve as Metsera's preferred supply partner for developed markets, including the United States and Europe
- 

Partnership grants Amneal a license to commercialize Metsera's products in select emerging markets, including India, Southeast Asia and Africa

 **METSERA HEADQUARTERS**
NEW YORK

 **AMNEAL HEADQUARTERS**
NEW JERSEY

 **NEW GREENFIELD FACILITIES**
INDIA

 **METSERA PREFERRED SUPPLY PARTNER**

 **LICENSE TO COMMERCIALIZE METSERA PRODUCTS IN SELECTED COUNTRIES**



INDIA FACILITIES KEY STATS



Amneal to break ground on two new greenfield manufacturing facilities **by end of 2024**



Total net cost to Amneal of between **\$150M and \$200M**, net of contributions from Metsera and government incentives

Highly complementary collaboration provides Amneal with new high-growth vector to drive long-term value creation and Metsera with high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable rapid product development and anticipated commercial launches

“At Amneal, our mission to provide access to high-quality, affordable and essential medicines has never been more critical, and it’s imperative that patients have affordable access to this new category of medicines.”

CHINTU AND CHIRAG PATEL
Co-Chief Executive Officers of Amneal



“Amneal is the ideal partner to best position us to advance our clinical stage pipeline, get ahead of the innovation curve with new treatment options and improve access globally to this class of life-changing medicines.”

CLIVE MEANWELL
Executive Chairman of Metsera



WHIT BERNARD
Chief Executive Officer of Metsera

FORWARD LOOKING STATEMENT

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: statements regarding the size of the GLP-1 category, our ability to access obesity markets, our ability to launch obesity-related products and the timeline thereof, our ability to receive certain tax incentives, our ability to build a manufacturing facility, our ability to capitalize on similar opportunities and other non- historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

